Welcome to our dedicated page for Aurora Spine news (Ticker: ASAPF), a resource for investors and traders seeking the latest updates and insights on Aurora Spine stock.
Aurora Spine Corporation (ASAPF) generates a steady stream of news around its spinal implant platforms, biologics portfolio, and participation in medical and investor events. The company’s releases highlight developments in minimally invasive spine surgery, interventional pain management, and bone density–matched implant technology.
Recent announcements emphasize Aurora Spine’s DEXA Technology platform, including the DEXA-C cervical fusion system and the DEXA-L anterior lumbar interbody fusion device, which the company describes as bone-mimicking implants engineered to match a patient’s bone density and quality. Other news focuses on the SiLO Sacroiliac Joint Fusion System, which Aurora reports has been used in more than 2,500 procedures, and the AERO Lumbar Fusion System, a minimally invasive facet fusion device cleared for use from C2 to S1.
Investors and clinicians following ASAPF news will also see updates on Aurora Biologics, a division dedicated to allograft-based biologic solutions designed to support spinal fusion and work in concert with the company’s mechanical implants. Patent issuances, such as those covering the ZIP implant family and bone density scan–matched orthopedic implants, further illustrate Aurora’s focus on intellectual property around spinal implant design.
This news feed captures product launches, clinical usage milestones, conference participation at meetings like NASS and ASPN, and scheduled financial result releases and investor presentations. Users can monitor these updates to understand how Aurora Spine presents the evolution of its spine technologies, surgeon adoption, and broader corporate activities over time.
Aurora Spine has announced the approval for a multicenter study of its DEXA-C™ Cervical Interbody System, aimed at improving spinal surgery outcomes. Seven sites have been selected, three are pending approval, with patient enrollment anticipated soon. The clinical trial will involve 80 subjects, assessing the system's effectiveness in anterior cervical discectomy and fusion procedures. Aurora's patented DEXA™ technology targets varying bone densities to enhance fusion success. Key outcomes will be monitored at multiple post-surgery intervals, focusing on fusion assessment and patient-reported results.
Aurora Spine Corporation (OTCQB: ASAPF) announced IRB approval for a multicenter study of its DEXA-C Cervical Interbody System, aimed at anterior cervical interbody fusion in patients with degenerative disc disease. This system utilizes Aurora's patented DEXA technology, designed to match implants with a patient’s bone density. The study will involve 10 sites across the U.S. with data from at least 80 subjects. Initial beta-testing responses have been positive, with researchers optimistic about improved surgical outcomes. The study will evaluate fusion success and subsidence metrics at various follow-up intervals.
Aurora Spine Corporation (TSXV:ASG, OTCQB:ASAPF) will present at the Planet MicroCap Showcase: VIRTUAL 2022 on December 7, 2022, at 10:00 AM EST. President and CEO Trent Northcutt and CFO Chad Clouse will lead the session, followed by a Q&A. Attendees can register for 1on1 meetings or view the presentation via the conference's online platform. Aurora Spine focuses on innovative, minimally invasive spinal devices aimed at improving surgical outcomes. For more information, visit aurora-spine.com.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) will release its third-quarter financial results for the period ended September 30, 2022, on November 21, 2022. Following the release, management will hold a conference call at 11:00 a.m. ET to discuss the results, which can be accessed via phone or a live webcast. The replay of this call will be available until November 28, 2022. Aurora Spine focuses on innovative, minimally invasive spinal implant technologies aimed at improving surgical outcomes.
Aurora Spine Corporation recently announced positive interim results from the REFINE Study on its ZIP™ MIS Interspinous Fusion System. The study, involving 54 patients, showed that 82% of participants experienced improvement after 3 months, with 65% reporting significant enhancements in pain and function. This data, published in Pain and Therapy, highlights the device's effectiveness and safety. Conducted by 11 doctors, the study aims to address the significant unmet need in treating lumbar spinal stenosis. Further results are expected at the 12-month follow-up.
Aurora Spine Corporation is set to participate in the 2022 North American Spine Society (NASS) Annual Meeting from October 12-15 in Chicago. The company will showcase innovative products like the newly FDA cleared SiLO TFX SI Fusion System, designed for sacroiliac joint fusion surgery, and DEXA Technology products for spinal procedures. CEO Trent Northcutt highlighted the importance of the event for showcasing their advancements and growing their sales pipeline, anticipating a strong momentum for the remainder of fiscal 2022 and into 2023.
Aurora Spine Corporation (OTCQB: ASAPF) has been awarded the 2022 Annual Spine Technology Award for its innovative DEXA Technology™ Bone Density-Matched Interbody Implants. Recognized by RRY Publications LLC and Orthopedics this Week, this technology adjusts spinal implants to match patients’ bone density, enhancing surgical outcomes. The award will be presented at the 37th Annual Meeting of the North American Spine Society in Chicago. Aurora Spine emphasizes that DEXA Technology™ represents a significant advancement in spinal implants, merging conventional machining, 3D printing, and additive manufacturing.
Aurora Spine Corporation (OTCQB: ASAPF) has received FDA 510(k) clearance for its SiLO TFX MIS Sacroiliac Joint Fixation System. This patented device is designed to enhance patient outcomes in spinal surgery through minimally invasive techniques. A detailed announcement regarding this system is expected on October 6, 2022. The clearance is a significant milestone for Aurora Spine, as it underscores the company's commitment to advancing spinal care technology.
Aurora Spine Corporation (TSXV: ASG, OTCQB: ASAPF) announced its participation in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company will present a panel discussion titled Simplifying the Complex, featuring CEO Trent Northcutt and Clinical Education Director Krissy Ramey, available at 9:00 AM ET on September 28. Virtual 1x1 meetings with management will also be conducted. Aurora Spine focuses on innovative spinal implant technologies aimed at improving surgical outcomes, with more information available on their website.
Aurora Spine Corporation reported record quarterly revenue of $4.1 million for Q2 2022, marking a 68% year-over-year increase and 15% sequential growth from Q1. The company achieved positive EBITDAC of $96,285 compared to losses in previous quarters. Key highlights include receiving FDA clearances for the ZIP™ family of implants and the DEXA SOLO-L™ spinal fusion system, along with the issuance of a new patent for ZIPFlex™ Technology. The gross margin improved to 52.6%, reflecting successful sales strategies and increased use of proprietary products.
FAQ
What is the current stock price of Aurora Spine (ASAPF)?
What is the market cap of Aurora Spine (ASAPF)?
